Close
Top Videos
Top Searches
Moods
Black Lives Matter
Chill
Christmas
Commute
Energy boosters
Feel-Good
Focus
Party
Pride
Romance
Sad
Sleep
Workout
Genres
African
Arabic
Blues
Bollywood & Indian
Christian & Gospel
Classical
Country and Americana
Dance and electronic
Decades
Family
Folk and acoustic
Hip-hop
Indie and alternative
J-Pop
Jazz
K-Pop
Latin
Mandopop & Cantopop
Metal
Pop
R&B and Soul
Reggae and Caribbean
Rock
Soundtracks and musicals
The VENICE-1 trial: venetoclax monotherapy in R/R CLL
02:08
|
Download MP3
Related Videos
5:11
iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma
3:08
Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸
0:44
Early detection and interception across hematological cancers
1:31
Frontline treatment for CLL: the changing paradigm
2:01
The evolution of BCL2 inhibition in CLL
2:08
The VENICE-1 trial: venetoclax monotherapy in R/R CLL
1:26
Prognostic and predictive biomarkers in CLL and their potential in guiding treatment decisions
1:11
Gene therapy for SCD: unanswered questions
2:26
An insight into the aims of the Eurasian Hematology-Oncology Group
2:13
Personalizing the timing of SCT in patients with myelofibrosis
2:13
Collaboration and cooperation in hematology-oncology research
1:13
The main treatment goals in LR-MDS and how these differ from HR-MDS
3:11
Defining and identifying ultra-high-risk multiple myeloma
3:56
Autoimmune cytopenias in CLL and the impact of targeted therapies
3:02
The role of asparaginase in the treatment of ALL
1:13
Using integrative multiomics to explain myeloma progression and evolution of refractory disease
0:47
Advice for physicians when managing bispecific antibody treatment for patients with myeloma
1:32
Factors contributing to the pathogenesis of ICAHT
1:54
Nivolumab + ibrutinib for patients with Richter’s transformation
2:55
A model including CD49d expression to predict outcomes in patients with CLL treated with ibrutinib
5:11 3:08 0:44 1:31 2:01 2:08 1:26 1:11 2:26 2:13 2:13 1:13 3:11 3:56 3:02 1:13 0:47 1:32 1:54 2:55
